Trends in Cardiovascular and Cancer Mortality Among Texas Residents with Cancer between 2010 and 2019
Author(s)
Ted Sohn1, Won Seog Choi, BS2, Sola Han, PharmD, PhD2, Chanhyun Park, MEd, RPh, PhD2;
1University of Texas College of Pharmacy, Graduate Student, Austin, TX, USA, 2University of Texas College of Pharmacy, Austin, TX, USA
1University of Texas College of Pharmacy, Graduate Student, Austin, TX, USA, 2University of Texas College of Pharmacy, Austin, TX, USA
Presentation Documents
OBJECTIVES: Cancer and cardiovascular disease (CVD) are the two leading causes of death in Texas, posing a significant public health burden. While advances in cancer care have improved survival rates among patients with cancer, CVD-related mortality remains disproportionately higher in patients with cancer compared to the general population. We evaluated long-term trends and characteristics of cancer-related and CVD-related mortality among Texas residents with cancer.
METHODS: This retrospective study used 2010-2019 Texas Cancer Registry data, including newly diagnosed cancer patients aged 20 years and older. Cancer sites were categorized using SEER ICD-O-3 codes (C000-C809). Cancer (C00-C97) and CVD (I00-I99) mortalities were identified using ICD-10. We used joinpoint regression analysis to examine the annual percentage change (APC) in age-adjusted incidence-based mortality. The CVD-to-cancer age-adjusted mortality ratio (CVD/cancer mortality) was computed for specific cancer sites and Texas counties. Pearson’s correlation was used to assess the association between CVD/cancer mortality and 1-year and 5-year survival rates.
RESULTS: Among 2,482,298 recoded mortalities, 890,106 (35.9%) were cancer-related, and 187,109 (7.5%) were CVD-related. Cancer-related mortality for all cancers showed a significant decline (APC = -2.71, p < 0.001), while CVD-related mortality significantly increased (APC = 2.00, p < 0.001). The highest CVD/cancer mortality ratios were observed in endocrine (0.52), prostate (0.48), and other male genital (0.39) cancers. A stronger association was observed between 5-year survival rates and CVD/cancer mortality (r = 0.890, t(14) = 7.32, p < 0.001) compared to 1-year survival rates and CVD/cancer mortality (r = 0.803, t(14) = 5.04, p < 0.001).
CONCLUSIONS: Mortality trends highlight the growing burden of CVD complications among Texas residents with cancer. Long-term survivors, particularly those with endocrine, prostate, and other male genital cancers, face an elevated risk of CVD-related mortality. These findings suggest the need for integrated cardio-oncology care strategies targeting long-term cancer survivors in Texas.
METHODS: This retrospective study used 2010-2019 Texas Cancer Registry data, including newly diagnosed cancer patients aged 20 years and older. Cancer sites were categorized using SEER ICD-O-3 codes (C000-C809). Cancer (C00-C97) and CVD (I00-I99) mortalities were identified using ICD-10. We used joinpoint regression analysis to examine the annual percentage change (APC) in age-adjusted incidence-based mortality. The CVD-to-cancer age-adjusted mortality ratio (CVD/cancer mortality) was computed for specific cancer sites and Texas counties. Pearson’s correlation was used to assess the association between CVD/cancer mortality and 1-year and 5-year survival rates.
RESULTS: Among 2,482,298 recoded mortalities, 890,106 (35.9%) were cancer-related, and 187,109 (7.5%) were CVD-related. Cancer-related mortality for all cancers showed a significant decline (APC = -2.71, p < 0.001), while CVD-related mortality significantly increased (APC = 2.00, p < 0.001). The highest CVD/cancer mortality ratios were observed in endocrine (0.52), prostate (0.48), and other male genital (0.39) cancers. A stronger association was observed between 5-year survival rates and CVD/cancer mortality (r = 0.890, t(14) = 7.32, p < 0.001) compared to 1-year survival rates and CVD/cancer mortality (r = 0.803, t(14) = 5.04, p < 0.001).
CONCLUSIONS: Mortality trends highlight the growing burden of CVD complications among Texas residents with cancer. Long-term survivors, particularly those with endocrine, prostate, and other male genital cancers, face an elevated risk of CVD-related mortality. These findings suggest the need for integrated cardio-oncology care strategies targeting long-term cancer survivors in Texas.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EPH152
Topic
Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory), SDC: Oncology